Hematology/Oncology

Bardia A, Schwaederle M, Curigliano G. Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply. N Engl J Med. 2025 Feb 20;392(8):830-831. doi:[...]

Sedrak MS, Asnani A. Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity? JACC CardioOncol. 2025 Feb;7(2):122-124. doi: 10.1016/j.jaccao.2025.01.004. PMID:[...]

Naing A, McKean M, Rosen LS, Sommerhalder D, Shaik NM, Wang IM, Le Corre C, Kern KA, Mishra NH, Pal SK. First-in-human phase I study[...]

Carlson S, Lin TL, Larson SM. Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma. Immunotherapy. 2025 Feb 17:1-12. doi: 10.1080/1750743X.2025.2461987. Epub[...]

Zhang TH, Shi Y, Komarova NL, Wordaz D, Kostelny M, Gonzales A, Abbaali I, Chen H, Bresson-Tan G, Dimapasoc M, Harvey W, Oh C, Carmona[...]

Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, Stevens DA, Malik SA, Shouse GP, Hamadani M, Oluwole OO, Perales MA,[...]

Monson S, Chen PJ, Gangi A, Waters K, Billet S, Hendifar A, Lu S, Zell JA, Gong J. Chemopreventive strategies for sporadic colorectal cancer: a[...]

Sun Y, Aliyari SR, Parvatiyar K, Wang L, Zhen A, Sun W, Han X, Zhang A, Kato E, Shi H, De Schutter E, McBride WH,[...]

Chavez JC, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani C, Lin Y, Riedell PA, Kekre N, de Vos S,[...]

Finn RS, Iyer R, Kalman RS, Parikh ND, Cabrera R, Babajanyan S, Kaseb AO. Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular[...]